Kimia Biosciences Share Price & Earnings Call Analysis

₹30.00+2.77% today

Market cap: ₹142 Cr
P/E: 19.74
ROE: 53.68%
PEG: 0.46
Price to sales: 1.26
Debt to equity: 1.96
52W high / low: ₹40.0 / ₹23.6
Sales growth (5Y): -2.84%
EBITDA margin: 12.58%
Net profit margin: 6.47%
Promoter holding: 74.94%
Sales (last year): ₹112 Cr

All 12 ratios ↓

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

See all potential multibaggers Where does Kimia Biosciences rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

1. Pick 3–15 stocks
2. Choose large, mid or small cap and your sectors
3. Get a portfolio built from the rankings

Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#	Company	Revenue guided	Margin guided	Market cap	P/E
1		40%+	Up 2%+	₹480 Cr	19.1
2		40%+	Up 0–2%	₹212 Cr	16.1
3		40%+	Flat	₹17,925 Cr	—
4		40%+	Flat	₹5,223 Cr	39.1
5		40%+	Flat	₹4,268 Cr	—
6		40%+	Flat	₹40 Cr	—

Sign up free to see every company in the sector ranking and track Kimia Biosciences.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Kimia Biosciences

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Kimia Biosciences

Quarterly Results

Quarter-by-quarter operating performance

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales +	28.80	22.66	24.23	24.20	26.14	30.30	22.40	28.18	30.10	38.24	23.58	34.00	30.10
Expenses +	31.75	28.02	25.87	26.16	27.19	26.14	18.69	24.81	25.10	30.06	21.05	31.48	23.54
Operating Profit	-2.95	-5.36	-1.64	-1.96	-1.05	4.16	3.71	3.37	5.00	8.18	2.53	2.52	6.56
OPM %	-10.24%	-23.65%	-6.77%	-8.10%	-4.02%	13.73%	16.56%	11.96%	16.61%	21.39%	10.73%	7.41%	21.79%
Other Income +	0.26	-0.69	0.13	0.64	0.58	0.30	0.08	0.37	0.42	0.44	0.85	-0.33	0.10
Interest	1.05	1.26	1.28	1.12	1.31	1.34	1.11	1.04	1.01	1.40	1.75	0.27	0.75
Depreciation	0.84	0.87	0.83	0.82	0.82	0.82	0.90	0.79	0.82	0.88	0.94	0.97	0.85
Profit before tax	-4.58	-8.18	-3.62	-3.26	-2.60	2.30	1.78	1.91	3.59	6.34	0.69	0.95	5.06
Tax %	-24.45%	-24.57%	-25.14%	-25.15%	-25.00%	22.17%	19.66%	15.71%	-27.30%	68.61%	13.04%	-7.37%	-7.71%
Net Profit +	-3.46	-6.17	-2.71	-2.44	-1.95	1.80	1.44	1.61	4.57	1.99	0.60	1.02	5.44
EPS in Rs	-0.73	-1.30	-0.57	-0.52	-0.41	0.38	0.30	0.34	0.97	0.42	0.13	0.22	1.15

Financials of Kimia Biosciences

Profit & Loss

Annual income statement trend

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	6	2	0	1	76	94	106	133	125	129	105	119	126
Expenses +	7	4	4	2	74	88	102	124	124	133	105	99	106
Operating Profit	-0	-2	-3	-1	2	6	4	8	1	-5	-0	20	20
OPM %	-5%	-110%	-1,779%	-56%	3%	6%	4%	6%	0%	-4%	-0%	17%	16%
Other Income +	0	1	0	0	1	1	1	2	1	0	2	1	1
Interest	0	0	1	0	1	2	3	3	4	4	5	5	4
Depreciation	0	0	0	0	1	1	2	2	3	3	3	3	4
Profit before tax	-1	-2	-4	-1	2	4	1	6	-5	-12	-7	14	13
Tax %	-1%	1%	0%	-8%	-4%	-1%	-13%	8%	-26%	-25%	-26%	29%
Net Profit +	-1	-2	-4	-1	2	4	1	5	-4	-9	-5	10	9
EPS in Rs	-1.06	-2.30	-5.48	-1.26	2.26	2.64	0.30	1.08	-0.78	-1.98	-1.12	2.03	1.92
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Financials of Kimia Biosciences

Balance Sheet

Capital structure and asset base

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	7	7	7	7	1	1	5	5	5	5	5	5	5
Reserves	-6	-7	-11	-12	0	4	9	14	10	1	-4	5	7
Borrowings +	0	1	7	14	34	31	34	45	41	53	44	33	36
Other Liabilities +	3	4	1	3	22	29	38	43	54	63	56	68	54
Total Liabilities	6	5	4	12	58	65	86	107	109	121	100	111	101
Fixed Assets +	4	3	3	7	13	16	18	28	35	34	32	33	34
CWIP	0	0	0	3	2	2	6	6	0	1	1	0	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets +	2	1	1	2	43	48	62	72	74	87	68	78	68
Total Assets	6	5	4	12	58	65	86	107	109	121	100	111	101

Financials of Kimia Biosciences

Cash Flows

Operating, investing and financing cash movement

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	1	0	-6	-1	-7	-3	0	6	8	-7	15	21
Cash from Investing Activity +	-0	0	-0	-6	-2	-2	-9	-14	-1	-3	-1	-5
Cash from Financing Activity +	-0	-0	6	7	10	4	8	8	-8	10	-13	-17
Net Cash Flow	-0	-0	0	0	0	-0	0	0	-0	-0	-0	0
Free Cash Flow	0	0	-6	-7	-10	-5	-9	-8	6	-10	13	17
CFO/OP	-187%	-2%	177%	85%	-287%	-45%	5%	71%	1,281%	136%	-3,021%	105%

Financials of Kimia Biosciences

Ratios

Working capital efficiency and return ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	22	56	173	20	141	113	128	115	88	87	96	113
Inventory Days	75	50	319	615	59	83	92	89	146	183	149	178
Days Payable	988	667	91	511	120	91	121	116	159	177	194	260
Cash Conversion Cycle	-891	-560	401	124	80	105	100	88	76	93	51	31
Working Capital Days	-58	-530	-173	-1,358	48	62	73	53	31	16	-30	-22
ROCE %	-25%	-127%	-188%	-10%	10%	16%	9%	16%	-2%	-12%	-4%	42%

Others in Pharmaceuticals & Biotechnology this season

Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industries vs Divis Laboratories vs Torrent Pharmaceuticals